CompletedPhase 3

Methylene Blue for the Treatment of Septic Shock

China88 participantsStarted 2024-08-05

Plain-language summary

The purpose of this study is to evaluate the efficacy and safety of methylene blue among adult patients with septic shock.

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. recent intake (4-weeks) of selective serotonin re-uptake inhibitors;
✕. pregnant;
✕. definitive pulmonary hypertension or chronic pulmonary heart disease;
✕. known glucose-6 phosphate dehydrogenase (G-6PD) deficiency;
✕. known allergy to methylene blue, phenothiazines, or food dyes;
✕. anticipated death from a preexisting disease within 90 days after randomization (as determined by the enrolling physician);
✕. refusal of the attending staff or patient family;
✕. participated in other study.

Time to shock reversal

Timeframe: 90 days after randomization

NCT IDNCT06532240

SponsorNorthern Jiangsu People's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-10-24